Good to hear Bloomberg asking cathie about inflation. Only problem is that she’s been calling for deflation for over a year now. It’s hilarious that she is blaming inflation and interest rates for her 75% decline. Those declines were completely attributable to cathies horrendous scaling and dip buying of obscenely overvalued stocks. If cathie thinks her funds have troughed she really needs to check her confidence at the door. Arkk probably troughs at $20.$ARK Innovation ETF(ARKK)$
Ascentage Pharma (6855.HK) today announced that it has released the updated results from a Phase Ib/II study of the Bcl-2 inhibitor lisaftoclax (APG-2575) in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) in a Poster Presentation at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting. Entering the fifth consecutive year in which company’s abstracts were selected for presentations by the ASCO Annual Meeting, Ascentage Pharma showcased results from multiple clinical trials of its five drug candidates, including favorable data of lisaftoclax, a key drug candidate of the company’s apoptosis-targeted pipeline, in Chinese patients with R/R CLL/SLL showing an objective response rate (ORR) of 67.4%. Lisaftoclax was well tole
Ascentage Pharma (6855.HK) today announced that it has released the updated results from a Phase Ib/II study of the Bcl-2 inhibitor lisaftoclax (APG-2575) in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) in a Poster Presentation at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting. Entering the fifth consecutive year in which company’s abstracts were selected for presentations by the ASCO Annual Meeting, Ascentage Pharma showcased results from multiple clinical trials of its five drug candidates, including favorable data of lisaftoclax, a key drug candidate of the company’s apoptosis-targeted pipeline, in Chinese patients with R/R CLL/SLL showing an objective response rate (ORR) of 67.4%. Lisaftoclax was well tole